Publikationen (32) Publikationen von FRANCISCO JAVIER BUSTAMANTE SCHNEIDER

2023

  1. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma

    Journal of Hepatology, Vol. 79, Núm. 1, pp. 93-108

2022

  1. Evaluation and Management of Liver Transplant Candidates with Prior Nonhepatic Cancer: Guidelines from the ILTS/SETH Consensus Conference

    Transplantation

2021

  1. Diagnosis and treatment of hepatocellular carcinoma. Update of the consensus document of the AEEH, AEC, SEOM, SERAM, SERVEI, and SETH

    Medicina Clinica, Vol. 156, Núm. 9, pp. 463.e1-463.e30

  2. Early tacrolimus exposure does not impact long-term outcomes after liver transplantation

    World Journal of Hepatology, Vol. 13, Núm. 3, pp. 362-374

  3. Liver transplant with controlled donors after circulatory death with normothermic regional perfusion and brain dead donors: A multicenter cohort study of transfusion, one-year graft survival and mortality

    International Journal of Surgery, Vol. 96

2020

  1. Controlled donation after circulatory death up to 80 years for liver transplantation: Pushing the limit again

    American Journal of Transplantation

  2. Long-Term Outcomes of Liver Transplantation in Patients With Pretransplant Renal Dysfunction Treated With Induction Therapy and Delayed Reduced De Novo Once-Daily Tacrolimus

    Transplantation Proceedings, Vol. 52, Núm. 5, pp. 1489-1492

2018

  1. Direct-acting antivirals are effective and safe in HCV/HIV-coinfected liver transplant recipients who experience recurrence of hepatitis C: A prospective nationwide cohort study

    American Journal of Transplantation, Vol. 18, Núm. 10, pp. 2513-2522

2016

  1. Favorable longterm outcomes of liver transplant recipients treated de novo with once-daily tacrolimus: Results of a single-center cohort

    Liver Transplantation, Vol. 22, Núm. 10, pp. 1391-1400

  2. Human immunodeficiency virus infection does not worsen prognosis of liver transplantation for hepatocellular carcinoma

    Hepatology, Vol. 63, Núm. 2, pp. 488-498

  3. Liver Retransplantation in Patients with HIV-1 Infection: An International Multicenter Cohort Study

    American Journal of Transplantation, Vol. 16, Núm. 2, pp. 679-687

  4. Safety and Efficacy of Early Everolimus When Calcineurin Inhibitors Are Not Recommended in Orthotopic Liver Transplantation

    Transplantation Proceedings, Vol. 48, Núm. 7, pp. 2506-2509

2015

  1. Decisiones terapéuticas en el tratamiento del carcinoma hepatocelular y patrones de uso de sorafenib. Resultados del estudio internacional observacional GIDEON en España

    Gastroenterologia y Hepatologia, Vol. 38, Núm. 4, pp. 263-273

  2. Renal function improvement in liver transplant recipients after early everolimus conversion: A clinical practice cohort study in Spain

    Liver Transplantation, Vol. 21, Núm. 8, pp. 1056-1065

2014

  1. IV Reunión de Consenso de la Sociedad Española de Trasplante Hepático 2012. Excepciones al Model for End-stage Liver Disease en la priorización para trasplante hepático

    Gastroenterologia y Hepatologia, Vol. 37, Núm. 2, pp. 83-91

2012

  1. Biliary complications in orthotopic liver transplantation using choledochocholedochostomy with a T-tube

    Transplantation Proceedings

  2. Does the transjugular intrahepatic portosystemic influence the outcome of liver transplantation?

    Transplantation Proceedings

  3. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation

    Liver Transplantation, Vol. 18, Núm. 1, pp. 45-52

  4. Is antithrombotic prophylaxis required after liver transplantation in HIV-infected recipients?

    American Journal of Transplantation

2011

  1. Advagraf de novo in liver transplantation: A single-center experience

    Transplantation Proceedings